TED Ted Baker Plc

    15 December 2004

   Tepnel Life Sciences PLC ("Tepnel") completes the acquisition of Diaclone   
                                 Research SAS                                  

Manchester, UK. 15 December 2004*. Tepnel (AIM: TED) announces today that it
has completed the acquisition of Diaclone Research SAS ("Diaclone") that was
previously announced on 30 July 2004.

Under the terms of the agreement, Tepnel has acquired Diaclone Research from
OPi SAS for a total consideration of Euro2.372 million and as of today assumes
control of its facilities based in Besan�on, France. Tepnel purchased Diaclone
by raising �4.2 million (before expenses) through the placing of 74,477,000
shares at a price of 5.65 pence per share with both existing and new
institutional shareholders in the UK and US.

Diaclone produces and customises monoclonal antibodies (mABs), complimentary
reagents and ELISA test kits. These products are currently sold as research
reagents to academic, biotechnology and pharmaceutical research scientists
worldwide. Diaclone's capabilities in immunobiology and immunoassay development
will additionally support all of Tepnel's existing strategic business units. It
is anticipated that the menu of capabilities offered to large pharmaceutical
customers through Tepnel's TSS group located in Scotland will be significantly
enhanced by the inclusion of custom therapeutic antibody development services
and protein purification and characterisation services.

Ben Matzilevich, Chief Executive Officer commented: "The acquisition of
Diaclone Research marks the next stage in our strategic corporate development
and significantly enhances the further expansion of our molecular diagnostic
product offering in USA, Europe, and the Far East. Diaclone Research will
provide us with the potential to develop the necessary mABs for diagnostic kits
for predicting and identifying a number of factors associated with organ
transplantation and rejection and autoimmune diseases. The acquisition of
Diaclone with its existing catalogue products and exceptional antibody
development capabilities is expected to have a positive impact on Tepnel's
revenues and earnings in 2005 and beyond."

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO

Gron Ffoulkes-Davies, Finance Director

0161 946 2200

Seymour Pierce

Mark Percy, Corporate Finance

0207 107 8000

De Facto Communications

Helena Podd

020 7940 1000

Notes to Editors

About Tepnel Life Sciences plc

Tepnel is a UK-based international life sciences instrumentation and services
company with a `tri-polar' strategy focused on providing the biomedical
industry with high-throughput automated DNA purification systems, manual DNA
purification kits and reagents, as well as scientific services for nucleic acid
purification, drug analysis, genotyping and genetically modified foods. Tepnel
was founded in 1992 to exploit DNA technology generated at UMIST (University of
Manchester Institute of Science and Technology) and is quoted on the AIM
segment of the London Stock Exchange (AIM: TED). More information on Tepnel can
be found at www.tepnel.com.



END

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024